VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX:RBM, OTCBB:RPBIF) today announced that Roche Diagnostics has terminated, effective September 30, 2011, the sales and distribution agreement between Roche and Response dated June 25, 2008. Under the terms of that agreement and related agreements, Roche Diagnostics had agreed to distribute Response’s cardiovascular point-of-care (POC) tests on the RAMP® 200 Reader in the US. Response does not expect the termination of its agreement with Roche Diagnostics to have a material impact on its financial results for the current year.
